<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Cellect Biotechnology Ltd.

    Cellect Biotechnology Ltd.

    Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai...

    Cellect Biotechnology Ltd. was founded in 2011 ...

    Filing Type:    PU
    Cyclacel Pharmaceuticals, Inc.

    Cyclacel Pharmaceuticals, Inc.

    Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...

    Cyclacel's founding scientist, Professor Sir Da...

    Filing Type:    PU
    INmune Bio Inc.

    INmune Bio Inc.

    INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...

    INmune Bio Inc. is a clinical stage biotechnolo...

    Filing Type:    PU
    Surmodics, Inc.

    Surmodics, Inc.

    Following two acquisitions of Creagh Medical and NorMedix – recognized innovator...

    Following two acquisitions of Creagh Medical an...

    Filing Type:    PU
    Bionik Laboratories Corp.

    Bionik Laboratories Corp.

    BIONIK is a global pioneering healthcare company on a mission to supply quality-of...

    BIONIK is a global pioneering healthcare compan...

    Filing Type:    PU
    CollPlant Biotechnologies Ltd.

    CollPlant Biotechnologies Ltd.

    CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...

    CollPlant is a regenerative medicine company fo...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Scholar Rock Holding Corporation

    Scholar Rock Holding Corporation

    Scholar Rock is a biopharmaceutical company focused on the discovery and developme...

    Scholar Rock is a biopharmaceutical company foc...

    Filing Type:    PU
    Clovis Oncology, Inc.

    Clovis Oncology, Inc.

    Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...

    Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...

    Filing Type:    PU
    Merrimack Pharmaceuticals, Inc.

    Merrimack Pharmaceuticals, Inc.

    Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is...

    Merrimack is a biopharmaceutical company based ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.